(Griffin, Perry, & Fleming, 2001) |
−0.066 |
0.817 |
2.48 |
2.19* |
21 |
EQ-5D |
Patients (within 3 months after onset) |
18+ |
(Griffin, Perry, & Fleming, 2001) |
−0.263 |
0.72 |
2.48 |
2.45* |
8 |
EQ-5D |
GPs |
Unknown |
(O'Brien, Goeree, Blackhouse, Smieja, & Loeb, 2003) |
Changed by day |
Not reported |
Not reported |
Not reported |
920 in placebo (639 with influenza |
Likert score transferred to VAS |
ILI patients (clinical trails antivirals GSK) |
18–64 |
(Turner et al., 2003) |
Changed by day |
Not reported |
Not reported |
Not reported |
See O'Brien at al |
Converted the Likert scores into VAS scores converted those into time-trade off scores |
ILI patients (clinical trails antivirals GSK) |
18–64 |
(Rothberg, Bellantonio, & Rose, 2003) |
0.25 |
1 |
Not reported |
Not reported |
15 |
HUI-3 |
Patients |
Working adults |
(Prosser et al., 2006) |
Not reported |
Not reported |
Not reported |
1.83 |
Not reported |
Time trade off |
Parents of children |
Children |
(Siddiqui & Edmunds, 2008) |
VAS scores as presented by O'Brien et.al |
0.85 |
Not reported |
1.68 for influenza ILI1.57 for non-influenza ILI |
See O'Brien et.al. |
VAS scores substracted from the baseline |
ILI patients |
18–64 |
(Sander et al., 2010) |
QALY scores as presented by Turner et.al. |
Not reported |
Not reported |
5.33 (0–19 yrs)6.35 (20–64 yrs) 10.69 (65+) |
See O'Brien et.al |
Uses published QALY weights and combines this with unpublished disease duration |
ILI patients |
18–64 |